Prenetics sells ACT Genomics to Delta, boosts cash reserves for growth

Prenetics, a global healthcare company listed on Nasdaq, has sold its stake in ACT Genomics to Delta Electronics for up to $71.8 million, gaining $46 million in cash, according to its GlobeNewswire press release. The move simplifies its business model and strengthens its consumer health focus with $86 million in cash reserves.